Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 27;13:4350. doi: 10.1038/s41467-022-31929-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — Each dot represents the neutralizing titer (FRNT₅₀) of an individual serum sample against a specific SARS-CoV-2 virus, which is labeled on the X-axis. Different colors represent the progenitor virus or different variants (specific mutations provided in Supplementary Table 1). Vaccinee serum samples were obtained from people who were vaccinated 2–6 weeks post second dose. The geometric mean FRNT₅₀ titers are represented in the graph as bars on top of the dots with geometric standard deviation. The geometric mean FRNT₅₀ titers (avg. titer) and average fold changes relative to reference virus 614D (set as 1-fold) are shown on the top of the graph. For each variant, the average fold change is the geometric mean of the individual FRNT₅₀ ratios (614D/variant) calculated for each serum sample. Dashed line represents the limit of quantitation (LOQ). For statistical analysis, a two-tailed Wilcoxon matched-pairs signed-rank test was performed by comparing each variant with 614D. Test statistics and P value are summarized in Supplementary Table 2. Source data are provided as a Source Data file. a Representative reporter viruses of all past and current WHO designated SARS-CoV-2 VOCs and VOIs were tested. N = 20 biologically independent sera examined over 16 viruses. LOQ = 5 for Omicron and LOQ = 40 for all other viruses. The average fold changes of all viruses differ significantly (P < 0.0001) from 614D, except for 614G (P = 0.8124). b VOCs and selected VOIs isolated from clinical specimens were tested. N = 26 biologically independent sera examined over 9 viruses. The average fold changes of all viruses differ significantly (P < 0.0001) from 614D, except for Alpha (P = 0.4833) and the two Lambda viruses (Lambda S1 and S2, P = 0.0796 and 0.7265, respectively). c Omicron subvariant BA.1, BA.1.1, and BA.2 isolated from clinical specimens were tested. N = 20 biologically independent sera examined over four viruses. The average fold changes of all viruses differ significantly (P < 0.0001) from 614D.